The newest pharmaceutical agreements may have limited near-term effect because they center on Medicaid instead of Medicare, according to analysts cited by STAT. Medicaid already receives the lowest prices among United States payers under the arrangements’ structure. The White House announced the agreements Monday with midsize biotechnology companies.
The companies agreed to reduce prices in Medicaid while receiving an exemption from required reductions in Medicare. That structure led analysts to question how much the voluntary agreements will accomplish immediately. President Trump has highlighted the deals while pursuing a drug-pricing approach he believes could benefit Republicans in the midterm elections.
The policy behind the agreements is known as most-favored nation, or MFN. Its stated premise is that the United States should pay prices similar to those paid by peer nations. President Trump announced the agreements in the Oval Office alongside health secretary Robert F. Kennedy Jr, commerce secretary Howard Lutnick, and CMS administrator Mehmet Oz.
STAT reported that the announcement involved several heads of U.S. pharmaceutical manufacturers gathered at the White House. The arrangements therefore pair Medicaid price reductions with continued protection from mandatory Medicare reductions, leaving analysts skeptical about their immediate reach.